Pure Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021
June 15, 2021 at 04:11 pm EDT
Share
PURE Bioscience, Inc. announced earnings results for the third quarter ended April 30, 2021. For the third quarter, the company announced total revenue was USD 561,000 compared to USD 2.221 million a year ago. Operating loss was USD 810,000 compared to operating Income of USD 474,000 a year ago. Net loss was USD 811,000 compared to net income of USD 473,000 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to basic earnings per share from continuing operations of USD 0.01 a year ago. For the nine months, total revenue was USD 3.068 million compared to USD 2.968 million a year ago. Operating loss was USD 1.583 million compared to USD 1.319 million a year ago. Net loss was USD 1.586 million compared to USD 1.318 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.
PURE Bioscience, Inc. is focused on developing and commercializing its proprietary antimicrobial products primarily in the food safety arena. The Company provides solutions to combat the health and environmental problems of pathogen and hygienic control. Its technology platform is based on patented, stabilized ionic silver, and its initial products contain silver dihydrogen citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers residual protection and formulates with other compounds. The Company offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. It also offers PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The Company sells its products directly and indirectly through third-party distributors.
PURE BIOSCIENCE, INC. 
